Inherited Metabolic Diseases: Emphasis on Myocardial Disease and Arrhythmogenesis
Author:
Sternick Eduardo Back
Publisher
Springer London
Reference77 articles.
1. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variants of Fabry’s disease with galactose-infusion therapy. N Engl J Med. 2001;345:25-32
2. Corr PB, Creer MH, Yamada KA, et al. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest. 1989;83:927-936
3. Wolf AM, Arad M, Ahmad F, et al. Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Circulation. 2008;117:144-154
4. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies. An American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816
5. Thiene G, Corrado D, Basso C. Cardiomyopathies: is it time for a molecular classification? Eur Heart J. 2004;25: 1772-1775